Triiodothyronine exchange rate

This article is about triiodothyronine as a hormone. For its use as a pharmaceutical drug, see

Liothyronine

.

IUPAC name

(2S)-2-amino-3-propanoic acid

Other names

triiodothyronine
T3
3,3′,5-triiodo-L-thyronine

ChEBI
ChemSpider
DrugBank
ECHA InfoCard 100.027.272
UNII
C15H12I3NO4
Molar mass 650.98 g·mol−1
NFPA 704

Except where otherwise noted, data are given for materials in their

standard state

(at 25 °C , 100 kPa).

Y verify (what is YN ?)
Infobox references

Triiodothyronine, also known as T3, is a thyroid hormone. It affects almost every physiological process in the body, including growth and development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the anterior pituitary gland. This pathway is part of a closed-loop feedback process: Elevated concentrations of T3, and T4 in the blood plasma inhibit the production of TSH in the anterior pituitary gland. As concentrations of these hormones decrease, the anterior pituitary gland increases production of TSH, and by these processes, a feedback control system stabilizes the amount of thyroid hormones that are in the bloodstream.

T3 is the true hormone. Its effects on target tissues are roughly four times more potent than those of T4. Of the thyroid hormone that is produced, just about 20% is T3, whereas 80% is produced as T4. Roughly 85% of the circulating T3 is later formed in the liver and anterior pituitary by removal of the iodine atom from the carbon atom number five of the outer ring of T4. In any case, the concentration of T3 in the human blood plasma is about one-fortieth that of T4. The half-life of T3 is about 2.5 days. The half-life of T4 is about 6.5 days.

Production

Synthesis from T4

T3 is the more metabolically active hormone produced from T4. T4 is deiodinated by three deiodinase enzymes to produce the more-active triiodothyronine:

  1. Type I present in liver, kidney, thyroid, and (to a lesser extent) pituitary; it accounts for 80% of the deiodination of T4.
  2. Type II present in CNS, pituitary, brown adipose tissue, and heart vessel, which is predominantly intracellular. In the pituitary, it mediates negative feedback on thyroid-stimulating hormone.
  3. Type III present in placenta, CNS, and hemangioma. This deiodinase converts T4 into reverse T3, which, unlike T3, is inactive.

T4 is synthesised in the thyroid gland follicular cells as follows.

  1. The sodium-iodide symporter transports two sodium ions across the basement membrane of the follicular cells along with an iodine ion. This is a secondary active transporter that utilises the concentration gradient of Na+ to move I− against its concentration gradient.
  2. I− is moved across the apical membrane into the colloid of the follicle.
  3. Thyroperoxidase oxidises two I− to form I2. Iodide is non-reactive, and only the more reactive iodine is required for the next step.
  4. The thyroperoxidase iodinates the tyrosyl residues of the thyroglobulin within the colloid. The thyroglobulin was synthesised in the ER of the follicular cell and secreted into the colloid.
  5. Thyroid-stimulating hormone (TSH) released from the anterior pituitary gland binds the TSH receptor (a Gs protein-coupled receptor) on the basolateral membrane of the cell and stimulates the endocytosis of the colloid.
  6. The endocytosed vesicles fuse with the lysosomes of the follicular cell. The lysosomal enzymes cleave the T4 from the iodinated thyroglobulin.
  7. These vesicles are then exocytosed, releasing the thyroid hormones.

Synthesis of T

3

from T

4

via deiodination. Synthesis of

Reverse T3

and

T2

is also shown.

Direct synthesis

The thyroid gland also produces small amounts of T3 directly. In the follicular lumen, tyrosine residues become iodinated. This reaction requires hydrogen peroxide. Iodine bonds carbon 3 or carbon 5 of tyrosine residues of thyroglobulin in a process called organification of iodine. The iodination of specific tyrosines yields monoiodotyrosine (MIT) and diiodotyrosine (DIT). One MIT and one DIT are enzymatically coupled to form T3. The enzyme is thyroid peroxidase.

The small amount of T3 could be important because different tissues have different sensitivities to T4 due to differences in deiodinase ubiquitination in different tissues link. This once again raises the question if T3 should be included in thyroid hormone replacement therapy (THRT).

Mechanism of action

T3 and T4 bind to nuclear receptors (thyroid hormone receptors). T3 and T4, although being lipophilic, are not able to passively diffuse through the phospholipid bilayers of target cells, instead relying on transmembrane iodothyronine transporters. The lipophilicity of T3 and T4 requires their binding to the protein carrier thyroid-binding protein (TBG) (thyroxine-binding globulins, thyroxine binding prealbumins, and albumins) for transport in the blood. The thyroid receptors bind to response elements in gene promoters, thus enabling them to activate or inhibit transcription. The sensitivity of a tissue to T3 is modulated through the thyroid receptors.

Transportation

T3 and T4 are carried in the blood, bound to plasma proteins. This has the effect of increasing the half-life of the hormone and decreasing the rate at which it is taken up by peripheral tissues. There are three main proteins that the two hormones are bound to. Thyroxine-binding globulin (TBG) is a glycoprotein that has a higher affinity for T4 than for T3. Transthyretin is also a glycoprotein, but only carries T4, with hardly any affinity at all for T3. Finally, both hormones bind with a low affinity to serum albumin, but, due to the large availability of albumin, it has a high capacity.

The saturation of binding spots on thyronine-binding globulin (TBG) by endogenous T3 can be estimated by the triiodothyronine resin uptake test. The test is performed by taking a blood sample, to which an excess of radioactive exogenous T3 is added, followed by a resin that also binds T3. A fraction of the radioactive T3 binds to sites on TBG not already occupied by endogenous thyroid hormone, and the remainder binds to the resin. The amount of labeled hormones bound to the resin is then subtracted from the total that was added, with the remainder thus being the amount that was bound to the unoccupied binding sites on TBG.

Effects

T3 increases the basal metabolic rate and, thus, increases the body’s oxygen and energy consumption. The basal metabolic rate is the minimal caloric requirement needed to sustain life in a resting individual. T3 acts on the majority of tissues within the body, with a few exceptions including the spleen and testis. It increases the production of the Na+/K+ -ATPase (which normally constitutes a substantial fraction of total cellular ATP expenditure) without disrupting transmembrane ion balance and, in general, increases the turnover of different endogenous macromolecules by increasing their synthesis and degradation.

Protein

T3 stimulates the production of RNA Polymerase I and II and, therefore, increases the rate of protein synthesis. It also increases the rate of protein degradation, and, in excess, the rate of protein degradation exceeds the rate of protein synthesis. In such situations, the body may go into negative ion balance.

Glucose

T3 potentiates the effects of the β-adrenergic receptors on the metabolism of glucose. Therefore, it increases the rate of glycogen breakdown and glucose synthesis in gluconeogenesis.

Lipids

T3 stimulates the breakdown of cholesterol and increases the number of LDL receptors, thereby increasing the rate of lipolysis.

Heart

T3 increases the heart rate and force of contraction, thus increasing cardiac output, by increasing β-adrenergic receptor levels in myocardium. This results in increased systolic blood pressure and decreased diastolic blood pressure. The latter two effects act to produce the typical bounding pulse seen in hyperthyroidism. It also upregulates the thick filament protein myosin, which helps to increase contractility. A helpful clinical measure to assess contractility is the time between the QRS complex and the second heart sound. This is often decreased in hyperthyroidism.

Development

T3 has profound effect upon the developing embryo and infants. It affects the lungs and influences the postnatal growth of the central nervous system. It stimulates the production of myelin, the production of neurotransmitters, and the growth of axons. It is also important in the linear growth of bones.

Neurotransmitters

T3 may increase serotonin in the brain, in particular in the cerebral cortex, and down-regulate 5HT-2 receptors, based on studies in which T3 reversed learned helplessness in rats and physiological studies of the rat brain.

Physiological function

Thyroid hormones act to increase protein turnover. This might serve an adaptive function in regard to long-term calorie restriction with adequate protein. When calories are in short supply, reduction in protein turnover may ameliorate the effects of the shortage.

Measurement

Triiodothyronine can be measured as free triiodothyronine, which is an indicator of triiodothyronine activity in the body. It can also be measured as total triiodothyronine, which also depends on the triiodothyronine that is bound to thyroxine-binding globulin.

Uses

Treatment of depressive disorders

The addition of triiodothyronine to existing treatments such as SSRIs is one of the most widely studied augmentation strategies for refractory depression, however success may depend on the dosage of T3. A long-term case series study by Kelly and Lieberman of 17 patients with major refractory unipolar depression found that 14 patients showed sustained improvement of symptoms over an average timespan of two years, in some cases with higher doses of T3 than the traditional 50 µg required to achieve therapeutic effect, with an average of 80 µg and a dosage span of 24 months; dose range: 25-150 µg. The same authors published a retrospective study of 125 patients with the two most common categories of bipolar disorders II and NOS whose treatment had previously been resistant to an average of 14 other medications. They found that 84% experienced improvement and 33% experienced full remission over a period of an average of 20.3 (standard deviation of 9.7). None of the patients experienced hypomania while on T3.

Use as a fat loss supplement

3,5-Diiodo-L-thyronine and 3,3′-diiodo-L-thyronine are used as ingredients in certain over-the-counter fat-loss supplements, designed for bodybuilding. Several studies have shown that these compounds increase the metabolization of fatty acids and the burning of adipose fat tissue in rats.

Alternative medicine

Triiodothyronine has been used to treat Wilson’s syndrome, an alternative medical diagnosis not recognized as a medical condition by mainstream medicine. This diagnosis involves various non-specific symptoms that are attributed to the thyroid, despite normal thyroid function tests. The American Thyroid Association has raised concern that the prescribed treatment with triiodothyronine is potentially harmful.

See also

  • Polar T3 syndrome

References

  1. ^ Bowen, R. (2010-07-24). “Physiologic Effects of Thyroid Hormones”. Colorado State University. Retrieved 2013-09-29. 
  2. ^ “How Your Thyroid Works – “A delicate Feedback Mechanism””. endocrineweb. 2012-01-30. Retrieved 2013-09-29. 
  3. ^ “Cytomel (Liothyronine Sodium) Drug Information”. RxList. 2011-01-03. Retrieved 2013-09-29. 
  4. ^ Irizarry, Lisandro (23 April 2014). “Thyroid Hormone Toxicity”. Medscape. WedMD LLC. Retrieved 2 May 2014. 
  5. ^ Boron, W. F. (2005). Medical Physiology: A Cellular And Molecular Approach. Philadelphia, PA: Elsevier / Saunders. p. 1300. ISBN 1-4160-2328-3. LCCN 2004051158. 
  6. ^ Lazar, MA; Chin, WW (December 1990). “Nuclear thyroid hormone receptors”. J. Clin. Invest. : 1777–82. doi:10.1172/JCI114906. PMC 329808 . PMID 2254444. 
  7. ^ Dietrich, J. W.; Brisseau, K.; Boehm, B. O. (2008). “Resorption, Transport und Bioverfügbarkeit von Schilddrüsenhormonen” . Deutsche Medizinische Wochenschrift (in German). (31–32): 1644–8. doi:10.1055/s-0028-1082780. PMID 18651367. 
  8. ^ References used in image are found in image article in Commons:Commons:File:Thyroid_system.png#References.
  9. ^ triiodothyronine resin uptake test from Farlex Medical Dictionary, citing: Mosby’s Medical Dictionary, 8th edition. 2009, Elsevier.
  10. ^ “Thyroid physiology and tests of function”. Anaesthetist.com. 
  11. ^ Martin, P.; Brochet, D.; Soubrie, P.; Simon, P. (1985). “Triiodothyronine-induced reversal of learned helplessness in rats”. Biological Psychiatry. (9): 1023–5. doi:10.1016/0006-3223(85)90202-1. PMID 2992618. 
  12. ^ Fontana, L.; Klein, S.; Holloszy, J.O.; Premachandra, B.N. (2006). “Effect of long-term calorie restriction with adequate protein and micronutrients”. J. Clin. Endocrinol. Metab. (8): 3232–3235. doi:10.1210/jc.2006-0328. PMID 16720655. 
  13. ^ Roth, G.S.; Handy, A.M.; Mattison, J.A.; Tilmont, E.M.; Ingram, D.K.; Lane, M.A. (2002). “Effects of dietary calorie restriction and ageing on thyroid hormones of rhesus monkeys”. Horm. Metab. Res. (7): 378–382. doi:10.1055/s-2002-33469. 
  14. ^ Military Obstetrics & Gynecology – Thyroid Function Tests In turn citing: Operational Medicine 2001, Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300
  15. ^ a b Kelly, T. F.; Lieberman, D. Z. (2009). “Long term augmentation with T3 in refractory major depression”. Journal of Affective Disorders. (1–2): 230–3. doi:10.1016/j.jad.2008.09.022. ISSN 0165-0327. PMID 19108898. 
  16. ^ Kelly, T. F.; Lieberman, D. Z. (2009). “The use of triiodothyronine as an augmentation agent in treatment-resistant bipolar II and bipolar disorder NOS”. Journal of Affective Disorders. (3): 222–6. doi:10.1016/j.jad.2008.12.010. PMID 19215985. 
  17. ^ Lombardi, A.; Lanni, A.; Moreno, M.; Brand, M. D.; Goglia, F. (1998). “Effect of 3,5-di-iodo-L-thyronine on the mitochondrial energy-transduction apparatus”. The Biochemical Journal. (1): 521–6. doi:10.1042/bj3300521. PMC 1219168 . PMID 9461551. 
  18. ^ Lanni, A. (2005). “3,5-Diiodo-L-thyronine powerfully reduces adiposity in rats by increasing the burning of fats”. The FASEB Journal. (11): 1552–4. doi:10.1096/fj.05-3977fje. ISSN 0892-6638. PMID 16014396. 
  19. ^ “ATA Statement on “Wilson’s Syndrome””. American Thyroid Association. 

External links

  • Triiodothyronine bound to proteins in the PDB
  • T3 at Lab Tests Online

en.wikipedia.org
Exchange of triiodothyronine derived from thyroxine with circulating triiodothyronine as studied in the rat.

MedLine Citation:

PMID:  455743     Owner:  NLM     Status:  MEDLINE    

Abstract/OtherAbstract:

At present it is widely assumed that T3 derived from T4 is rapidly and totally exchangeable within the volume of distribution of T3 secreted by the thyroid into the bloodstream. This concept is implied when conclusions are drawn from comparisons between a biological effect in a responsive tissue and circulating T3 and T4 levels. Such conclusions are often in conflict with those derived by comparing the biological effect with the concentrations of T3 and T4 in the responsive tissue itself. Thus, it appeared important to test the above assumption directly. Thyroidectomized rats have been treated for 4-4 1/2 days with a mixture of 131I labelled T4 (131T4) and 125I labelled T3 (125T3), which was either injected twice daily or administered by continuous i.v. infusion. The rats were bled, perfused, and their plasma and tissues submitted to extraction and paper chromatography. If the tested assumption were correct, the ratio between the T3 derived from T4 and the T3 injected as such (namely, the 131T3/125T3 ratio) should be the same in plasma, liver, kidney, heart, muscle, etc. It was evident that the 131T3/125T3 ratio was not the same for different tissues. The differences were not merely due to artefactual deiodinations. The presence of small amounts of 131I and 125I containing compounds in the T3 spot was considered as highly unlikely, though not totally excluded. The data thus suggest that T3 derived from T4 and the injected (or thyroidally secreted) T3 might not be totally exchangeable within an observation period which is considerably longer than the one for which complete equilibrium was previously assumed. If so, changes in the size of the T4 pool, or in the rate of T4 conversion to T3, might affect the concentration of T3 in a given tissue to an extent not disclosed from the circulating T3 levels alone. Several possible consequences of the present findings are discussed.

Authors:

M J Obregon; F Roelfsema; G Morreale de Escobar; F Escobar del Rey; A Querido

Related Documents :

16026513 – Effects of melatonin on lipid peroxidation and anti-oxidant enzyme activity in rats wit…
11012083 – Effect of pineal indoles on activities of the antioxidant defense enzymes superoxide di…
11108253 – Leptin deficiency induced by fasting impairs the satiety response to cholecystokinin.

Publication Detail:

Type:  Journal Article    

Journal Detail:

Title:  Clinical endocrinology     Volume:  10     ISSN:  0300-0664     ISO Abbreviation:  Clin. Endocrinol. (Oxf)     Publication Date:  1979 Mar 

Date Detail:

Created Date:  1979-09-17     Completed Date:  1979-09-17     Revised Date:  2003-11-14    

Medline Journal Info:

Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  ENGLAND    

Other Details:

Languages:  eng     Pagination:  305-15     Citation Subset:  IM    

Export Citation:

APA/MLA Format     Download EndNote     Download BibTex MeSH Terms

Descriptor/Qualifier:

Animals

MaleRatsThyroid Gland / secretion

ThyroidectomyThyroxine / metabolism*

Tissue DistributionTriiodothyronine / metabolism*

Chemical

Reg. No./Substance:

6893-02-3/Triiodothyronine; 7488-70-2/Thyroxine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

www.biomedsearch.com

Top Currencies

USD – US Dollar

EUR – Euro

GBP – Pound Sterling

CAD – Canadian Dollar

All Currencies

AED – Emirati Dirham

AFN – Afghan Afghani

ALL – Albanian Lek

AMD – Armenian Dram

ANG – Netherlands Antillean Guilder

AOA – Angolan Kwanza

ARS – Argentine Peso

AUD – Australian Dollar

AWG – Aruban Florin

AZN – Azerbaijani Manat

BAM – Bosnia And Herzegovina Convertible Mark

BBD – Barbadian Dollar

BDT – Bangladeshi Taka

BGN – Bulgarian Lev

BHD – Bahraini Dinar

BIF – Burundian Franc

BMD – Bermudian Dollar

BND – Brunei Dollar

BOB – Bolivian Boliviano

BRL – Brazilian Real

BSD – Bahamian Dollar

BTC – Bitcoin

BTN – Bhutanese Ngultrum

BWP – Botswana Pula

BYR – Belarusian Ruble

BZD – Belize Dollar

CDF – Congolese Franc

CHF – Swiss Franc

CLP – Chilean Peso

CNY – Chinese Yuan Renminbi

COP – Colombian Peso

CRC – Costa Rican Colon

CUC – Cuban Convertible Peso

CUP – Cuban Peso

CVE – Cape Verdean Escudo

CZK – Czech Koruna

DJF – Djiboutian Franc

DKK – Danish Krone

DOP – Dominican Peso

DZD – Algerian Dinar

EEK – Estonian Kroon

EGP – Egyptian Pound

ERN – Eritrean Nakfa

ETB – Ethiopian Birr

FJD – Fijian Dollar

FKP – Falkland Islands Pound

GEL – Georgian Lari

GGP – Guernsey Pound

GHS – Ghana Cedi

GIP – Gibraltar Pound

GMD – Gambian Dalasi

GNF – Guinean Franc

GTQ – Guatemalan Quetzal

GYD – Guyanese Dollar

HKD – Hong Kong Dollar

HNL – Honduran Lempira

HRK – Croatian Kuna

HTG – Haitian Gourde

HUF – Hungarian Forint

IDR – Indonesian Rupiah

ILS – Israeli New Shekel

IMP – Isle of Man Pound

INR – Indian Rupee

IQD – Iraqi Dinar

IRR – Iranian Rial

ISK – Icelandic Krona

JEP – Jersey Pound

JMD – Jamaican Dollar

JOD – Jordanian Dinar

JPY – Japanese Yen

KES – Kenyan Shilling

KGS – Kyrgyzstani Som

KHR – Cambodian Riel

KMF – Comorian Franc

KPW – North Korean Won

KRW – South Korean Won

KWD – Kuwaiti Dinar

KYD – Cayman Islands Dollar

KZT – Kazakhstani Tenge

LAK – Lao Kip

LBP – Lebanese Pound

LKR – Sri Lankan Rupee

LRD – Liberian Dollar

LSL – Lesotho Loti

LTL – Lithuanian Litas

LVL – Latvian Lat

LYD – Libyan Dinar

MAD – Moroccan Dirham

MDL – Moldovan Leu

MGA – Malagasy Ariary

MKD – Macedonian Denar

MMK – Burmese Kyat

MNT – Mongolian Togrog

MOP – Macanese Pataca

MRO – Mauritanian Ouguiya

MUR – Mauritian Rupee

MVR – Maldivian Rufiyaa

MWK – Malawian Kwacha

MXN – Mexican Peso

MYR – Malaysian Ringgit

MZN – Mozambican Metical

NAD – Namibian Dollar

NGN – Nigerian Naira

NIO – Nicaraguan Cordoba

NOK – Norwegian Krone

NPR – Nepalese Rupee

NZD – New Zealand Dollar

OMR – Omani Rial

PAB – Panamanian Balboa

PEN – Peruvian Nuevo Sol

PGK – Papua New Guinean Kina

PHP – Philippine Peso

PKR – Pakistani Rupee

PLN – Polish Zloty

PYG – Paraguayan Guarani

QAR – Qatari Riyal

RON – Romanian Leu

RSD – Serbian Dinar

RUB – Russian Ruble

RWF – Rwandan Franc

SAR – Saudi Riyal

SBD – Solomon Islands Dollar

SCR – Seychellois Rupee

SDG – Sudanese Pound

SEK – Swedish Krona

SGD – Singapore Dollar

SHP – Saint Helena Pound

SLL – Sierra Leonean Leone

SOS – Somali Shilling

SPL – Seborga Luigino

SRD – Surinamese Dollar

STD – São Tomé And Príncipe Dobra

SVC – Salvadoran Colon

SYP – Syrian Pound

SZL – Swazi Lilangeni

THB – Thai Baht

TJS – Tajikistani Somoni

TMM – Old Turkmenistan Manat

TMT – Turkmenistan Manat

TND – Tunisian Dinar

TOP – Tongan Pa?anga

TRY – Turkish Lira

TTD – Trinidad And Tobago Dollar

TVD – Tuvaluan Dollar

TWD – New Taiwan Dollar

TZS – Tanzanian Shilling

UAH – Ukrainian Hryvnia

UGX – Ugandan Shilling

UYU – Uruguayan Peso

UZS – Uzbekistani Som

VEB – Venezuela Bolivar

VEF – Venezuelan Bolivar

VND – Vietnamese Dong

VUV – Vanuatu Vatu

WST – Samoan Tala

XAF – Central African Cfa Franc

XCD – East Caribbean Dollar

XDR – Special Drawing Rights

XOF – West African Cfa Franc

XPF – CFP Franc

YER – Yemeni Rial

ZAR – South African Rand

ZMK – Zambian Kwacha

ZWD – Zimbabwean Dollar

www.currency.wiki

Leave a Reply

Your email address will not be published. Required fields are marked *